Literature DB >> 29140521

Prevalence of Catatonia and Its Moderators in Clinical Samples: Results from a Meta-analysis and Meta-regression Analysis.

Marco Solmi1,2, G Giorgio Pigato3, Beatrice Roiter1, Argentina Guaglianone1, Luca Martini1, Michele Fornaro4, Francesco Monaco2, Andrè F Carvalho2,5, Brendon Stubbs2,6,7, Nicola Veronese2,8, Christoph U Correll2,9,10.   

Abstract

Catatonia is an independent syndrome that co-occurs with several mental and medical conditions. We performed a systematic literature review in PubMed/Scopus until February 2017 and meta-analyzed studies reporting catatonia prevalence. Across 74 studies (cross-sectional = 32, longitudinal = 26, retrospective = 16) providing data collected from 1935 to 2017 across all continents, mean catatonia prevalence was 9.0% (k = 80, n = 110764; 95% CI = 6.9-11.7, I2 = 98%, publication bias P < .01), decreasing to 7.8% (k = 19, n = 7612, 95% CI = 7-8.7, I2 = 38.9%) in a subgroup with low heterogeneity. Catatonia prevalence was 23.9% (k = 8, n = 1168, 95% CI = 10-46.9, I2 = 96%) in patients undergoing ECT/having elevated creatinine phosphokinase. Excluding ECT samples, the catatonia prevalence was 8.1% (k = 72, n = 109606, 95% CI = 6.1-10.5, I2 = 98%, publication bias P < .01), with sensitivity analyses demonstrating that country of study origin (P < .001), treatment setting (P = .003), main underlying condition (P < .001), and sample size (P < .001)moderated catatonia prevalence, being highest in Uganda (48.5%, k = 1) and lowest in Mexico (1.9%, 95% CI = 0.4-8.8, I2 = 67%, k = 2), highest in nonpsychiatric out- or inpatient services (15.8%, 95% CI = 8.1-28.4, I2 = 97%, k = 15)and lowest in psychiatric outpatients services (3.2%, 95% CI = 1.7-6.1, I2 = 50%, k = 3), highest in presence of medical or neurological illness with no comorbid psychiatric condition (20.6%, 95% CI = 11.5-34.2, I2 = 95%, k = 10)and lowest in mixed psychiatric samples (5.7%, 95% CI = 4.2-7.7, I2 =98%, k = 43), highest in studies with sample sizes <100 (20.7%, 95% CI = 12.8-31.6, I2 = 90%, k = 17) and lowest in studies with sample sizes >1000 (2.3%, 95% CI = 1.3-3.9, I2 = 99%, k = 16). Meta-regression showed that smaller sample size (P < .01) and less major depressive disorder (P = .02) moderated higher catatonia prevalence. Year of data collection did not significantly moderate the results. Results from this first meta-analysis of catatonia frequencies across time and disorders suggest that catatonia is an epidemiologically and clinically relevant condition that occurs throughout several mental and medical conditions, whose prevalence has not decreased over time and does not seem to depend on different rating scales/criteria. However, results were highly heterogeneous, calling for a cautious interpretation.

Entities:  

Mesh:

Year:  2018        PMID: 29140521      PMCID: PMC6101628          DOI: 10.1093/schbul/sbx157

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  111 in total

1.  Electroconvulsive therapy in adolescent and adult psychiatric inpatients--a retrospective chart design.

Authors:  Daniel Stein; Larissa Kurtsman; Shaul Stier; Yulia Remnik; Sorin Meged; Abraham Weizman
Journal:  J Affect Disord       Date:  2004-11-01       Impact factor: 4.839

Review 2.  Catatonia in patients with autism: prevalence and management.

Authors:  Luigi Mazzone; Valentina Postorino; Giovanni Valeri; Stefano Vicari
Journal:  CNS Drugs       Date:  2014-03       Impact factor: 5.749

Review 3.  Measuring catatonia: a systematic review of rating scales.

Authors:  Pascal Sienaert; Jonas Rooseleer; Jürgen De Fruyt
Journal:  J Affect Disord       Date:  2011-03-21       Impact factor: 4.839

4.  A retrospective study of 34 catatonic patients: analysis of clinical care and treatment.

Authors:  Joep H A M Tuerlings; Jeroen A van Waarde; Bastiaan Verwey
Journal:  Gen Hosp Psychiatry       Date:  2010-10-13       Impact factor: 3.238

5.  Delayed onset of late movement-related cortical potentials and abnormal response to lorazepam in catatonia.

Authors:  G Northoff; A Pfennig; M Krug; P Danos; A Leschinger; A Schwarz; B Bogerts
Journal:  Schizophr Res       Date:  2000-09-01       Impact factor: 4.939

6.  Schizophrenia psychopathology in a Kuwaiti Arab sample.

Authors:  Muhammad A Zahid; Jude U Ohaeri
Journal:  Psychopathology       Date:  2010-08-25       Impact factor: 1.944

7.  Acute behavioral crises in psychiatric inpatients with autism spectrum disorder (ASD): recognition of concomitant medical or non-ASD psychiatric conditions predicts enhanced improvement.

Authors:  Vincent Guinchat; Cora Cravero; Lautaro Diaz; Didier Périsse; Jean Xavier; Claire Amiet; Isabelle Gourfinkel-An; Nicolas Bodeau; Lee Wachtel; David Cohen; Angèle Consoli
Journal:  Res Dev Disabil       Date:  2015-01-07

8.  Gender differences in the frequency of schizophrenic subtypes in unselected hospitalized patients.

Authors:  S Beratis; J Gabriel; S Hoidas
Journal:  Schizophr Res       Date:  1997-02-28       Impact factor: 4.939

9.  Severe and uncommon involuntary movement disorders due to psychotropic drugs.

Authors:  S Stübner; E Rustenbeck; R Grohmann; G Wagner; R Engel; G Neundörfer; H-J Möller; H Hippius; E Rüther
Journal:  Pharmacopsychiatry       Date:  2004-03       Impact factor: 5.788

10.  Catatonia in depression: prevalence, clinical correlates, and validation of a scale.

Authors:  S E Starkstein; G Petracca; A Tesón; E Chemerinski; M Merello; R Migliorelli; R Leiguarda
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-03       Impact factor: 10.154

View more
  19 in total

Review 1.  Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series.

Authors:  Nancy J Butcher; Erik Boot; Anthony E Lang; Danielle Andrade; Jacob Vorstman; Donna McDonald-McGinn; Anne S Bassett
Journal:  Am J Med Genet A       Date:  2018-05-19       Impact factor: 2.802

2.  The Fragile Brain: Stress Vulnerability, Negative Affect and GABAergic Neurocircuits in Psychosis.

Authors:  Stephan F Taylor; Tyler B Grove; Vicki L Ellingrod; Ivy F Tso
Journal:  Schizophr Bull       Date:  2019-10-24       Impact factor: 9.306

Review 3.  [Poison in the filter: implementing detoxification procedures in schizophrenia].

Authors:  Ekkehardt Kumbier
Journal:  Nervenarzt       Date:  2019-11       Impact factor: 1.214

4.  Cortical Contributions to Distinct Symptom Dimensions of Catatonia.

Authors:  Dusan Hirjak; Katharina M Kubera; Georg Northoff; Stefan Fritze; Alina L Bertolino; Cristina E Topor; Mike M Schmitgen; Robert C Wolf
Journal:  Schizophr Bull       Date:  2019-10-24       Impact factor: 9.306

5.  Evaluating the Effectiveness of an Educational Module for the Bush-Francis Catatonia Rating Scale.

Authors:  Joshua R Wortzel; Daniel D Maeng; Andrew Francis; Mark A Oldham
Journal:  Acad Psychiatry       Date:  2022-01-07

6.  Low physical activity is associated with two hypokinetic motor abnormalities in psychosis.

Authors:  Sebastian Walther; Irena Vladimirova; Danai Alexaki; Lea Schäppi; Kathrine S F Damme; Vijay A Mittal; Stewart A Shankman; Katharina Stegmayer
Journal:  J Psychiatr Res       Date:  2021-11-08       Impact factor: 4.791

7.  The occurrence of catatonia diagnosis in acute care hospitals in the United States: A national inpatient sample analysis.

Authors:  James Luccarelli; Mark Kalinich; Thomas H McCoy; Carlos Fernandez-Robles; Gregory Fricchione; Felicia Smith; Scott R Beach
Journal:  Gen Hosp Psychiatry       Date:  2022-05-24       Impact factor: 7.587

8.  Management and outcomes of catatonia: A prospective study in urban South Africa.

Authors:  Zukiswa Zingela; Louise Stroud; Johan Cronje; Max Fink; Stephan van Wyk
Journal:  SAGE Open Med       Date:  2022-06-20

Review 9.  Movement disorders in psychiatric patients.

Authors:  Laura Perju-Dumbrava; Peter Kempster
Journal:  BMJ Neurol Open       Date:  2020-12-01

10.  Lithium-Associated Hyperparathyroidism Followed by Catatonia.

Authors:  Srinagesh Mannekote Thippaiah; Rachel E Fargason; Jayasudha G Gude; Shankarapura N Muralidhara; Badari Birur
Journal:  AACE Clin Case Rep       Date:  2020-12-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.